Plasma metabolism marker combination for diagnosing or monitoring colorectal cancer and application

A technology for metabolic markers and colorectal cancer, applied to the combination and application of plasma metabolic markers, can solve the problems of prone to false positives, poor sensitivity of plasma Septin9 gene methylation detection, and high missed diagnosis rate, so as to reduce trauma and missed diagnosis rate effect

Pending Publication Date: 2022-07-05
THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Colonoscopy is an invasive examination with poor compliance
FIT detection is prone to false positives, high rate of missed diagnosis, high cost of multi-target stool DNA detection, poor sensitivity of plasma Septin9 gene methylation detection, low cost-benefit ratio

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Plasma metabolism marker combination for diagnosing or monitoring colorectal cancer and application
  • Plasma metabolism marker combination for diagnosing or monitoring colorectal cancer and application
  • Plasma metabolism marker combination for diagnosing or monitoring colorectal cancer and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] This embodiment provides a method for screening plasma metabolic markers for diagnosing colorectal cancer, comprising the following steps:

[0029] S1, collect sample

[0030] In this study, peripheral venous blood plasma samples were collected from 100 healthy controls and 88 colorectal cancer patients from the Clinical Medical Research Center after obtaining patient consent. Among them, healthy controls were from people without intestinal diseases after physical examination; colorectal cancer patients were diagnosed by colorectal endoscopy and postoperatively. All samples had no history of any other malignant tumors, no other major systemic diseases, and no history of chronic diseases with long-term medication. The samples in each group were matched for age and sex.

[0031] Blood collection time was in the early morning on an empty stomach. All plasma samples were centrifuged and stored in a -80°C refrigerator. During the study, plasma samples were taken out and t...

Embodiment 2

[0069] Embodiment 2 Detection and verification

[0070] In this example, peripheral venous blood plasma samples from 405 healthy controls and 364 colorectal cancer patients from 2 independent medical research centers were collected after obtaining patient consent. Among them, healthy controls were from people without intestinal diseases after physical examination; colorectal cancer patients were diagnosed by colorectal endoscopy and postoperatively. All samples had no history of any other malignant tumors, no other major systemic diseases, and no history of chronic diseases with long-term medication. The samples in each group were matched for age and sex, and the blood collection time was in the early morning on an empty stomach. All plasma samples were centrifuged and stored in a -80°C refrigerator. During the study, plasma samples were taken out and thawed for subsequent analysis.

[0071] The detection conditions and data analysis methods in this example are the same as t...

Embodiment 3

[0087] This embodiment provides a detection kit for diagnosing or monitoring colorectal cancer, comprising:

[0088] (1) Standards for metabolic markers: N-acetylphenylalanine, 1,7-dimethylxanthine, 8,15-dihydroxyeicosatetraenoic acid, N-acetyl-5-methoxy Gelatin, 2-amino-4-hydroxypteridine, serotonin, lysophosphatidylcholine (15:0), methylmaleic acid, N-methyl-alpha-aminoisobutyric acid, thymine, alone Subpackage or mixed package.

[0089] (2) Solvent:

[0090] Pure methanol and 50% acetonitrile in water were used for sample extraction.

[0091] 50% acetonitrile in water can be used as a solvent for dissolving the standard.

[0092] (3) Internal standard: L-phenylalanine.

[0093] The screening method using the detection kit for diagnosing or monitoring colorectal cancer in this embodiment includes the following steps:

[0094] S1, collect plasma samples, preprocess, and obtain test solution.

[0095] S2, use LC-MS to analyze and detect the test solution to obtain N-acet...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention provides a plasma metabolism marker combination for diagnosing or monitoring colorectal cancer and application of the plasma metabolism marker combination, and metabolism markers are selected from N-acetylphenylalanine, 1, 7-dimethylxanthine, 8, 7-dimethylxanthine, 8, 7-dimethylxanthine, 8, 7-dimethylxanthine and 8, 7-dimethylxanthine. The composition is one or a combination of more of 1, 15-dihydroxy eicosatetraenoic acid, N-acetyl-5-methoxytryptamine, 2-amino-4-hydroxy pteridine, 5-hydroxytryptamine, lysophosphatidylcholine (15: 0), methylmaleic acid, N-methyl-alpha-aminoisobutyric acid and thymine. The ten metabolic markers provided by the invention can accurately diagnose colorectal cancer, have high sensitivity and strong specificity, can replace the existing method for diagnosing colorectal cancer based on blood and excrement detection, reduce trauma and missed diagnosis rate, reduce detection cost, and have clinical use and popularization values.

Description

technical field [0001] The invention relates to the technical field of detection, in particular to a combination and application of plasma metabolic markers for diagnosing or monitoring colorectal cancer. Background technique [0002] Colorectal cancer (CRC), also known as colorectal cancer, is a common malignant tumor of the digestive system. According to the World Health Organization's International Cancer Research Center, there will be about 1.93 million new cases of colorectal cancer in the world in 2020, ranking third among malignant tumors. There are about 560,000 new cases of colorectal cancer and about 280,000 deaths in China, ranking the second and fifth among all cancers, respectively. [0003] It is estimated that the 5-year survival rate of colorectal cancer can reach more than 65%, the 5-year survival rate of patients with early diagnosis and treatment can reach more than 90%, and the 5-year survival rate of advanced patients is less than 15%. Therefore, early...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/04
CPCG01N30/02G01N30/04G01N2030/042G01N2030/045
Inventor 金鹏杜灵彬许俊锋谢惠李娜余东亮王昕陶玉荣朱陈
Owner THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap